ArticleTranslational lung cancer research2026
Using an artificial intelligence tool to improve the recognition of pseudoprogression in pleural mesothelioma patients treated with immunotherapy: a case series.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pseudoprogression, defined as initial radiological tumor growth followed by treatment response, can complicate treatment response assessment in patients receiving immunotherapy. In pleural mesothelioma (PM) patients treated with immunotherapy reliable identification of pseudoprogression remains challenging with the modified Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1 criteria. Automated volumetric assessment using an artificial intelligence (AI) tool (ARTIMES) may provide additional insight into tumor response patterns. We aim to describe cases of pseudoprogression identified using the ARTIMES criteria in PM patients treated with immunotherapy. Case Description: We performed a retrospective observational study of adult PM patients treated with immunotherapy at a tertiary center between January 1, 2013 and July 1, 2022. Tumor volumes were automatically segmented and quantified using the ARTIMES model. Patients demonstrating disease progression according to ARTIMES criteria followed by subsequent tumor volume decrease were evaluated for pseudoprogression. The results were presented in graphs depicting tumor volume, treatment duration, and the start and stop dates of immunotherapy. Among 368 PM patients treated with immunotherapy, 8 patients met inclusion criteria for confirmed pseudoprogression. All patients were male, with a median age of 67.5 years. Most patients had epithelioid histology (75.0%). All patients showed initial volumetric progression on early follow-up imaging, followed by objective tumor volume reduction either during continued immunotherapy or after treatment discontinuation. Volumetric tumor tracking enabled visualization of delayed responses that would have been difficult to interpret using standard imaging comparisons alone. Conclusions: Pseudoprogression occurs in a subset of PM patients treated with immunotherapy. Automated volumetric tumor assessment can help identify pseudoprogression patterns. Integrating volumetric analysis with clinical evaluation may reduce premature discontinuation of potentially effective immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.